MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2009 |
 |
 |
| Monday, 27 July 2009 16:11 |
|
Management of the Company will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM EDT on August 3, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; and Corporate Vice President and Chief Financial Officer, Matthew Pfeffer. To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (800) 879-7630 or (203) 369-4000 and entering conference number 7091668. A replay will also be available on MannKind's website for 14 days. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA® and MKC253. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MKC253 is currently in phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.comBiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
VALENCIA, Calif.--MannKind Corporation (Nasdaq: MNKD) will release its 2009 second quarter financial results on Monday, August 3, 2009.
Free Phone Trade Alerts
